Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy

Open access
Zhang, Panpan, Ma, Yuanyuan, Lv, Chao, Huang, Miao, Li, Mingzhen, Dong, Bin, Liu, Xijuan, An, Guo, Zhang, Wenlong, Zhang, Jianzhi, Zhang, Liyi, Zhang, Shanyuan, Yang, Yue · 2016 · Cancer Science

Abstract

To assess the association of the programmed cell death ligand 1 (PD‐L1) with cisplatin‐based neo‐adjuvant chemotherapy (NAC) response, we investigated the level of PD‐L1 and found increased PD‐L1 expression in chemo‐resistant tumors compared with chemo‐sensitive tumors according to RNA‐Seq analysis. In a cohort of 92 patients with NAC, the positive staining of PD‐L 1 was correlated with TNM stage, lower sensitive‐response rates and shorter overall survival rates. In another 30 paired tumor specimens pre‐ and post‐chemotherapy, the patients with high PD‐L 1 expression post‐chemotherapy had a worse outcome and higher stable disease rate. CD 8+ tumor‐infiltrating lymphocytes were found to be related to chemosensitive response and better prognosis and negative PD‐L 1 expression. Furthermore, in two patient‐derived xenograft models and cell lines A 549 and PC‐9, cisplatin upregulated PD‐L 1 expression, and the enhancement of PD‐L 1 in cancer cell lines was in a drug dose‐dependent manner. Moreover, the depletion of PD‐L 1 significantly reduced cisplatin resistance. When phosphatidylinositol 3‐kinase/protein kinase B signaling was inhibited by corresponding inhibitors, PD‐L 1 expression was downregulated and apoptosis was upregulated in the cisplatin‐treated cancer cells. These results suggest that the upregulation of PD‐L 1 promotes a resistance response in lung cancer cells that might be through activation of the phosphatidylinositol 3‐kinase/protein kinase B pathway and suppression of tumor‐infiltrating lymphocytes. The high expression of PD‐L 1 after NAC could be an indication of therapeutic resistance and poor prognosis in patients with non‐small‐cell lung cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.13072

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 184

Metadata

Authors
Zhang, P., Ma, Y., Lv, C., Huang, M., Li, M., Dong, B., Liu, X., An, G., Zhang, W., Zhang, J., Zhang, L., Zhang, S., & Yang, Y.
Venue
Cancer Science
Publisher
Wiley
Published
2016-11
Volume
107
Issue
11
Pages
1563-1571
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2517381625
Cited by
184
References
7
FWCI
10.04
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy. https://app.cochat.ai/papers/10.1111/cas.13072
The paper
Zhang, P., Ma, Y., Lv, C., Huang, M., Li, M., Dong, B., Liu, X., An, G., Zhang, W., Zhang, J., Zhang, L., Zhang, S., & Yang, Y. (2016). Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy. Cancer Science. https://doi.org/10.1111/cas.13072

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.